Top-Rated StocksTop-RatedNASDAQ:ARVN Arvinas (ARVN) Stock Price, News & Analysis $22.69 +1.05 (+4.85%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Arvinas Stock (NASDAQ:ARVN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arvinas alerts:Sign Up Key Stats Today's Range$21.17▼$22.7150-Day Range$21.64▼$28.0452-Week Range$20.28▼$53.08Volume744,090 shsAverage Volume718,161 shsMarket Capitalization$1.56 billionP/E RatioN/ADividend YieldN/APrice Target$61.08Consensus RatingModerate Buy Company OverviewArvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Read More… Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Arvinas Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks62nd Percentile Overall ScoreARVN MarketRank™: Arvinas scored higher than 62% of companies evaluated by MarketBeat, and ranked 612th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingArvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArvinas has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arvinas' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arvinas are expected to decrease in the coming year, from ($3.32) to ($4.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arvinas' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.81% of the outstanding shares of Arvinas have been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in Arvinas has recently decreased by 5.58%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.81% of the outstanding shares of Arvinas have been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in Arvinas has recently decreased by 5.58%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.32 News SentimentArvinas has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Arvinas this week, compared to 4 articles on an average week.Search Interest5 people have searched for ARVN on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows2 people have added Arvinas to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.23% of the stock of Arvinas is held by insiders.Percentage Held by Institutions95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arvinas' insider trading history. Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address ARVN Stock News HeadlinesArvinas price target lowered to $88 from $90 at BMO CapitalNovember 20 at 10:19 PM | markets.businessinsider.comStephens & Co. Initiates Coverage of Arvinas (ARVN) with Overweight RecommendationNovember 19 at 1:21 PM | msn.comDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.November 21, 2024 | DTI (Ad)Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To ExplodeNovember 19 at 10:09 AM | insidermonkey.comArvinas initiated with an Overweight at StephensNovember 18 at 5:16 PM | markets.businessinsider.comClearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular EdemaNovember 7, 2024 | globenewswire.comMorgan Stanley Sticks to Their Hold Rating for Arvinas Holding Company (ARVN)November 4, 2024 | markets.businessinsider.comArvinas to Participate in Upcoming Investor ConferencesNovember 4, 2024 | globenewswire.comSee More Headlines ARVN Stock Analysis - Frequently Asked Questions How have ARVN shares performed this year? Arvinas' stock was trading at $41.16 at the start of the year. Since then, ARVN shares have decreased by 44.9% and is now trading at $22.69. View the best growth stocks for 2024 here. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) issued its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.88) by $0.20. Arvinas's quarterly revenue was up 196.0% compared to the same quarter last year. When did Arvinas IPO? Arvinas (ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO. Who are Arvinas' major shareholders? Arvinas' top institutional investors include FMR LLC (4.20%), RTW Investments LP (4.05%), Bellevue Group AG (3.47%) and State Street Corp (2.39%). Insiders that own company stock include John G Houston, Sean A Cassidy, Ian Taylor, Ronald Peck, Briggs Morrison and Liam Ratcliffe. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings10/30/2024Today11/20/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/25/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARVN CUSIPN/A CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees445Year FoundedN/APrice Target and Rating Average Stock Price Target$61.08 High Stock Price Target$88.00 Low Stock Price Target$40.00 Potential Upside/Downside+169.2%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($4.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-367,300,000.00 Net MarginsN/A Pretax Margin-190.01% Return on Equity-50.26% Return on Assets-24.87% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio4.17 Sales & Book Value Annual Sales$78.50 million Price / Sales19.86 Cash FlowN/A Price / Cash FlowN/A Book Value$11.99 per share Price / Book1.89Miscellaneous Outstanding Shares68,710,000Free Float65,119,000Market Cap$1.56 billion OptionableOptionable Beta1.96 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:ARVN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.